Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission

Trial Profile

Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Cancer vaccine NY-ESO-1 (Primary) ; Poly ICLC (Primary) ; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jan 2015 Status changed from not yet recruiting to completed according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top